Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in South Dakota: - Avera Cancer Institute-Aberdeen — Aberdeen, South Dakota
- Avera Cancer Institute - Mitchell — Mitchell, South Dakota
- Avera Cancer Institute at Pierre — Pierre, South Dakota
- Rapid City Regional Hospital — Rapid City, South Dakota
- Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in South Dakota: - Rapid City Regional Hospital — Rapid City, South Dakota
- Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
- Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in South Dakota: - Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
- Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…
Sponsor: AstraZeneca
NCT ID: NCT05774951
Sites in South Dakota: - Research Site — Aberdeen, South Dakota
- Research Site — Mitchell, South Dakota
- Research Site — Pierre, South Dakota
- Research Site — Sioux Falls, South Dakota
- Research Site — Yankton, South Dakota
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in South Dakota: - Sanford Cancer Center ( Site 0059) — Sioux Falls, South Dakota
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in South Dakota: - Avera Cancer Institute — Sioux Falls, South Dakota
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in South Dakota: - Sanford Clinical Research — Sioux Falls, South Dakota
Phase 1, Phase 2 Recruiting Industry
A Study of Emi-Le in Participants with Solid Tumors
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT05377996
Sites in South Dakota: - Avera Cancer Institute — Sioux Falls, South Dakota
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in South Dakota: - Monument Health Rapid City Hospital — Rapid City, South Dakota
Recruiting Industry
For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later. A way to find the…
Sponsor: Tempus AI
NCT ID: NCT07211178
Sites in South Dakota: - Sanford - Sioux Falls — Sioux Falls, South Dakota
Recruiting Academic/Other
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patien…
Sponsor: Sanford Health
NCT ID: NCT01793168
Sites in South Dakota: - Sanford Health — Sioux Falls, South Dakota